After decades of limited progress, the development of novel anti-TB medicines was revitalised at the start of the 21st century through new initiatives and investments. This has resulted in innovations in treatment regimens thanks to new compounds becoming available and the re-purposing of existing drugs. However, progress has been relatively slow for a disease that, until the emergence of the COVID-19 pandemic, has remained the top infec- tious killer worldwide. Accelerated action is there- fore necessary to reach the ambitious target of ‘‘ending TB’’ set by the WHO within its new Global Strategy (2016–2030). Read Here.
top of page
bottom of page